Read More

Psychedelic industry reacts to FDA’s MDMA decision, study retraction

The U.S. Food and Drug Administration’s decision to reject MDMA-assisted therapy for post-traumatic stress disorder sent ripples through the psychedelic industry. The FDA issued a complete response letter to Lykos Therapeutics on Friday for its new drug application for midomafetamine capsules, an MDMA-assisted therapy for PTSD in adults. The agency …